The intensive statin therapy myth

Michael Shechter, Roy Beigel, Shlomi Matetzky, Dov Freimark, Pierre Chouraqui

Research output: Contribution to journalArticlepeer-review

Abstract

Statins play an important role in the treatment and prevention of coronary artery disease and atherosclerosis. Currently, however, despite its important qualities, the use of statin therapy in the treatment of CAD patients ranges only between 30 and 60% in Europe, the United States and Israel. A wide gap still exists between the numerous scientific publications demonstrating the beneficial effects of statins and the low rate of implementing the guidelines in practice. A Medline search up to June 2005 on all prospective, double-blind, randomized clinical trials evaluating the impact of intensive statin therapy (any statin dose >40 mg/daily) on clinical outcomes after a 1 year follow-up revealed only eight trials. In all the eight trials, with a follow-up period of 12-60 months, intensive statin therapy was significantly more effective than and at least as safe as placebo or other standard statin regimens. Thus, based on the current evidence-based medicine, intensive statin therapy enables more patients with CAD to achieve the current National Cholesterol Education Program goal for low density lipoprotein, while ensuring a relatively high safety profile.

Original languageEnglish
Pages (from-to)683-687
Number of pages5
JournalIsrael Medical Association Journal
Volume7
Issue number11
StatePublished - Nov 2005

Keywords

  • Cholesterol
  • Coronary disease
  • Lipoproteins
  • Myocardial infarction

Fingerprint

Dive into the research topics of 'The intensive statin therapy myth'. Together they form a unique fingerprint.

Cite this